State the number first: Vertex Pharmaceuticals reported $12.0 billion in revenue for 2025. The two prior years were $11.0 billion (2024) and $9.9 billion (2023), all tagged in the XBRL of its annual reports — the FY2025 10-K and the FY2024 10-K. The story those three points tell is not drama. It is consistency.
By the numbers, that is roughly 11% growth in 2024 and about 9% in 2025 — a steady double-digit-billion franchise compounding at a measured pace. Set against the near-doubling of revenue at Lilly over a similar window, Vertex's curve looks almost boring. But boring, in pharma, is often the more durable thing: it usually signals a franchise with strong exclusivity and predictable demand rather than one riding a launch wave.
The quarterly data confirms the steadiness. Vertex's first-quarter 2026 10-Q tagged $3.0 billion of revenue for the three months ended March 31, 2026, against $2.8 billion in the comparable prior-year quarter — single-digit growth, quarter after quarter, with little of the volatility that marks a company dependent on episodic events.
What is behind the steadiness is the cystic-fibrosis franchise, a category where Vertex has long held a dominant position. A franchise like that throws off predictable cash that the company can redeploy — which is exactly what its filings describe it doing, funding the Casgevy gene-therapy collaboration and the Journavx pain program. The steady revenue line is, in effect, the funding source for the company's diversification bets.
One caution, as always: revenue is total company revenue, and a single new product can change the slope going forward. The three-year trend describes the recent past, not a guarantee. But the past it describes is unusually clean — three ascending figures with no air pockets.
These comparisons are possible because the EdgarBeast evidence index normalizes the revenue tags companies embed in their filings, so the same concept can be read year over year straight from the source. For Vertex, that source tells a patient-investor's favorite kind of story: up and to the right, without the whiplash.